massimo breccia
massimo breccia
Verified email at
Cited by
Cited by
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia
F Lo-Coco, G Avvisati, M Vignetti, C Thiede, SM Orlando, S Iacobelli, ...
New England Journal of Medicine 369 (2), 111-121, 2013
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
Experts in Chronic Myeloid Leukemia
Blood, The Journal of the American Society of Hematology 121 (22), 4439-4442, 2013
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
JL Steegmann, M Baccarani, M Breccia, LF Casado, V García-Gutiérrez, ...
Leukemia 30 (8), 1648-1671, 2016
Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non–high-risk acute promyelocytic leukemia: final results of the …
U Platzbecker, G Avvisati, L Cicconi, C Thiede, F Paoloni, M Vignetti, ...
Journal of Clinical Oncology 35 (6), 605-612, 2017
Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial …
F Lo-Coco, G Avvisati, M Vignetti, M Breccia, E Gallo, A Rambaldi, ...
Blood, The Journal of the American Society of Hematology 116 (17), 3171-3179, 2010
Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure
TP Hughes, MJ Mauro, JE Cortes, H Minami, D Rea, DJ DeAngelo, ...
New England Journal of Medicine 381 (24), 2315-2326, 2019
Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia
F Lo-Coco, G Cimino, M Breccia, NI Noguera, D Diverio, E Finolezzi, ...
Blood 104 (7), 1995-1999, 2004
Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population
F Efficace, M Baccarani, M Breccia, G Alimena, G Rosti, F Cottone, ...
Blood, The Journal of the American Society of Hematology 118 (17), 4554-4560, 2011
Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia
G Rosti, F Palandri, F Castagnetti, M Breccia, L Levato, G Gugliotta, ...
Blood, The Journal of the American Society of Hematology 114 (24), 4933-4938, 2009
Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian …
NI Noguera, M Breccia, M Divona, D Diverio, V Costa, S De Santis, ...
Leukemia 16 (11), 2185-2189, 2002
Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic …
MT Voso, S Fenu, R Latagliata, F Buccisano, A Piciocchi, MA Aloe-Spiriti, ...
J Clin Oncol 31 (21), 2671-2677, 2013
Clinico-pathological characteristics of myeloid sarcoma at diagnosis and during follow-up: report of 12 cases from a single institution
M Breccia, F Mandelli, MC Petti, M D’Andrea, E Pescarmona, SA Pileri, ...
Leukemia research 28 (11), 1165-1169, 2004
Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib
F Efficace, M Baccarani, M Breccia, F Cottone, G Alimena, GL Deliliers, ...
Leukemia 27 (7), 1511-1519, 2013
Therapy-related myelodysplastic syndrome–acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem
R Latagliata, MC Petti, S Fenu, M Mancini, MAA Spiriti, M Breccia, ...
Blood, The Journal of the American Society of Hematology 99 (3), 822-824, 2002
Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment.
M Breccia, M Muscaritoli, Z Aversa, F Mandelli, G Alimena
Journal of clinical oncology: official journal of the American Society of …, 2004
Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features
M Breccia, G Avvisati, R Latagliata, I Carmosino, A Guarini, MS De Propris, ...
Leukemia 21 (1), 79-83, 2007
Identification of risk factors in atypical chronic myeloid leukemia
M Breccia, F Biondo, R Latagliata, I Carmosino, F Mandelli, G Alimena
Haematologica 91 (11), 1566-1568, 2006
Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study
F Efficace, M Baccarani, G Rosti, F Cottone, F Castagnetti, M Breccia, ...
British journal of cancer 107 (6), 904-909, 2012
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up
F Palandri, F Castagnetti, N Testoni, S Luatti, G Marzocchi, S Bassi, ...
Haematologica 93 (12), 1792-1796, 2008
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party
G Gugliotta, F Castagnetti, F Palandri, M Breccia, T Intermesoli, A Capucci, ...
Blood, The Journal of the American Society of Hematology 117 (21), 5591-5599, 2011
The system can't perform the operation now. Try again later.
Articles 1–20